Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-centre, single-dose, open-label, randomised, four-way cross-over study to evaluate and compare the pharmacokinetic parameters of a fixed dose combination of intravenous acetaminophen + intravenous ibuprofen, intravenous acetaminophen, intravenous ibuprofen and a fixed dose combination tablet of acetaminophen 325mg + ibuprofen 97.5mg, in healthy volunteers.

Trial Profile

Single-centre, single-dose, open-label, randomised, four-way cross-over study to evaluate and compare the pharmacokinetic parameters of a fixed dose combination of intravenous acetaminophen + intravenous ibuprofen, intravenous acetaminophen, intravenous ibuprofen and a fixed dose combination tablet of acetaminophen 325mg + ibuprofen 97.5mg, in healthy volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibuprofen/paracetamol (Primary) ; Ibuprofen/paracetamol (Primary) ; Ibuprofen; Paracetamol
  • Indications Pain
  • Focus Pharmacokinetics
  • Acronyms Maxi-IV PK
  • Sponsors AFT Pharmaceuticals
  • Most Recent Events

    • 04 Aug 2016 Status changed from not yet recruiting to completed.
    • 05 Jul 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top